$CTMX

Vanguard (CTMX) reports 0 shares; disaggregation after internal realignment

The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of CytomX Therapeutics Inc (CTMX) common stock as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries began reporting beneficial ownership separately, as permitted by SEC Release No. 34-39538. The filing indicates no voting or dispositive power over CTMX shares for The Vanguard Group itself.

Original reporting
Published Mar 27, 2026, 6:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 27, 2026, 7:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CTMX
Neutral
high confidence
Mentioned
$CTMX
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$CTMXNeutralLow
01

Why it matters

This administrative update indicates no active trading or ownership change, suggesting limited market impact.

02

Market read

The news has limited relevance to market dynamics, primarily affecting Vanguard's reporting structure rather than trading activity.

03

What to watch

The change is purely administrative, stemming from internal realignment, and does not reflect a market-driven decision or change in CTMX's fundamentals.

Timing: low

Background

Vanguard filed an amended Schedule 13G/A, reporting zero shares and beneficial ownership of CTMX as of March 13, 2026, due to internal realignment.

Company-level read

Ticker impact

$CTMXNeutralHigh confidence
Context

The news pertains to Vanguard's internal realignment affecting its ownership reporting of CytomX Therapeutics Inc (CTMX).

Expected impact

Minimal to no immediate impact on CTMX stock price.

Evidence & confidence

The filing reflects internal reporting adjustments rather than market-driven ownership changes, suggesting limited direct trading impact.

Market effects

Limited sector impact; the change is specific to Vanguard's reporting structure.

Minimal regional effects, as the news pertains to a U.S.-based SEC filing.

Negligible; primarily a regulatory reporting update without market-wide implications.

Counterpoint

Some traders might interpret the zero ownership report as a sign of Vanguard reducing exposure, potentially signaling a lack of confidence or strategic shift.

Key entities

  • Vanguard Group

    A major investment management company.

  • CytomX Therapeutics Inc

    A biopharmaceutical company focused on innovative cancer therapies.

Related articles

$CTMXMed

CytomX Therapeutics, Inc. (CTMX): Results of Operations and Financial Condition

CytomX Therapeutics, Inc. (CTMX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ctmx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Re

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.